SAHLGRENSKA ACADEMY SEMINARS
Speaker: Lee E. Goldstein, Associate Professor of Psychiatry, Neurology, Ophthalmology, Pathology & Laboratory Medicine, Biomedical Engineering, and Electrical & Computer Engineering, Boston University School of Medicine, College of Engineering, Photonics Center, and NIH Alzheimer’s Disease & CTE Center, Boston, MA, USA
Title: Concussion, Traumatic Brain Injury and Chronic Traumatic Encephalopathy – Lessons from the Battlefield, Ball Field, and Lab Bench
Host: Kaj Blennow email@example.com
Dr. Goldstein’s research focuses on degenerative diseases of the aging brain and eye. He received his baccalaureate from Columbia and MD-PhD (Neuroscience) from Yale. He completed clinical fellowships (medicine, psychiatry) and postdoctoral research (Alzheimer’s disease, Rudolph Tanzi) at Harvard. In 2001, he joined the Harvard faculty and established his laboratory as an NIH Beeson Scholar in Aging Research. His team discovered Alzheimer’s disease Aβ pathology in the lens of the eye (Lancet, 2003), the first evidence of AD outside the brain. His team subsequently showed that Alzheimer’s Aβ pathology is expressed decades earlier in lens than in brain, uncovered evidence linking Aβ lens pathology to early-onset cataracts in Down syndrome, and reported discovery of a new GWAS-significant Alzheimer’s risk gene (CTNND2; δ-catenin) that influences Aβ expression in lens and brain. This work led to development of a laser eye scanner for early Alzheimer’s detection now in clinical testing. He remained at Harvard until recruitment to Boston University (2008). His team reported chronic traumatic encephalopathy (CTE) in the first case series of blast-exposed military veterans and showed that blast-exposed mice also develop CTE pathology and cognitive deficits (Sci Transl Med, 2012). This study provided evidence linking blast exposure to CTE and uncovered novel mechanisms of blast neurotrauma (“bobblehead effect”). This study received international media attention, informed a Presidential Executive Order (2012), and supported development and testing of a novel therapeutic for TBI (Nature, 2015). His team recently uncovered mechanisms that differentially trigger concussion and CTE. Dr. Goldstein is inventor on numerous patents, founding scientist of a biotechnology company (Neuroptix, now Cognoptix), and co-developer of the first ophthalmic drug-device combination product approved by the FDA. He is the recipient of awards from NIH, American Federation for Aging Research, Alzheimer’s Association, Optical Society of America, Harvard Medical School, and Oxford University.
A light lunch will be served from 11.30 outside the venue on a first come – first served basis.
If you would like to come into contact with the speaker, please contact the host on his e-mail address.
Please join our group on LinkedIn for Sahlgrenska Academy Seminars: https://www.linkedin.com/groups/Sahlgrenska-Academy-Seminars-8480633/about
List of speakers: http://www.sahlgrenska.gu.se/sas/